Saturday 17 October 2026
Export MDXH’s income statement to Excel — free account
MDxHealth SA
MDXH Healthcare Diagnostics & Research
MDxHealth SA’s revenue for fiscal 2025 (year ended December 2025) was $107.9 million, up 19.8% from fiscal 2024. In the quarter to June 2026, revenue grew 12.0%, EPS fell 15.8%, free cash flow fell 200.2% and total debt rose 26.0%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
0.21
0.39
−65.00%
Follow MDXH
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.19 | 1.07 | 1.63 | 2.33 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(3.67) | (80.41) | 471.87 | 140.07 | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.93 | 1.62 | 2.14 | 2.88 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(20.09) | (172.65) | (106.99) | (50.46) | |
EV/FCF |
(15.24) | (59.13) | (54.25) | (36.08) | |
Quick Ratio |
0.91 | 1.38 | 0.88 | 0.98 | |
Current Ratio |
1.15 | 1.63 | 1.08 | 1.14 | |
Net Debt/EBITDA |
(31.34) | (12.41) | (17.30) | (138.99) | |
Debt/Assets |
78.77% | 64.75% | 57.25% | 55.71% | |
Debt/Equity |
(3.42) | (5.15) | (7.00) | (10.40) | |
Asset Turnover |
0.84 | 0.67 | 0.72 | 0.64 | |
Operating CF/Net income |
0.51 | 0.17 | (0.04) | (0.21) | |
Capex/Depreciation |
(0.02) | (0.15) | (0.02) | (0.12) | |
Interest Coverage |
(0.84) | (0.82) | (1.01) | (0.45) | |
Research and Development Expense of Revenue |
7.33% | 7.79% | 12.17% | 7.32% | |
Selling, General and Administrative Expense of Revenue |
72.03% | 74.91% | 63.54% | 65.79% | |
Intangible Assets out of Total Assets |
0.58 | 0.48 | 0.53 | 0.51 | |
Share Based Compensation of Revenue |
2.22% | 2.05% | 2.12% | 1.63% | |
Graham Net Nets |
(5.56) | (0.94) | (0.60) | (0.45) | |
Graham Number |
3.07 | 2.45 | 1.90 | 1.82 | |
Earnings Yield |
(175.61%) | (30.00%) | (18.49%) | (19.14%) | |
Free Cash Flow Yield |
(32.52%) | (2.55%) | (2.42%) | (3.42%) | |
Revenue per Share |
0.52 | 0.53 | 0.66 | 0.55 | |
Operating CF per Share |
(0.11) | (0.03) | 0.01 | 0.03 | |
Capex per Share |
0.00 | (0.01) | 0.00 | (0.01) | |
Free Cash Flow per Share |
(0.11) | (0.04) | 0.01 | 0.03 | |
Cash per Share |
0.37 | 0.83 | 0.58 | 0.64 | |
Shareholders Equity per Share |
(0.58) | (0.39) | (0.24) | (0.17) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.58) | (0.39) | (0.24) | (0.17) | |
Free Cash Flow |
(5.89) | (1.85) | 0.32 | 1.40 | |
Working Capital |
5.63 | 26.32 | 3.88 | 7.06 | |
Capital Expenditures |
(0.04) | (0.36) | (0.05) | (0.26) | |
Net Current Asset Value |
(119.46) | (113.17) | (106.64) | (104.32) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.01 | 0.00 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
15.32 | 14.90 | 14.56 | 16.62 | |
Average Payables |
8.65 | 9.81 | 9.17 | 9.89 | |
Average Inventory |
5.05 | 5.35 | 5.31 | 5.23 | |
Average Assets |
136.36 | 167.83 | 152.64 | 155.84 | |
Average Common Equity |
(15.64) | (7.13) | 1.37 | 4.37 |
Columns are period end dates